

# Syncona Update

July 2020



# Syncona

Building the next generation of healthcare companies

## Key Media Coverage

### Tempus:

The Times 01.07.20

Alex Ralph of The Times tipped Syncona as a stock to buy in the newspaper's share tips column, Tempus. The article highlighted Syncona's 20.4% uplift, in the two months prior to publication, and the portfolio's recent progress, with a particular eye on Freeline's expanded Series C financing. Alex advised readers to buy Syncona shares on the promise of the company's emerging second-generation assets that are emulating the success of more established companies in the portfolio.

### Make your investments fly high by picking the best of British

Mail on Sunday 11.07.20

In an article on the best of British investments, Rosie Murray-West reports in the Mail on Sunday that Syncona is a strong option for investing in the best of British biotech.

## Achilles Therapeutics

Developing novel cancer immunotherapies targeting clonal neoantigens

### Key Announcements

#### [Appointment of Daniel Hood as Chief Legal Officer](#)

07.07.2020

Daniel, a highly experienced lawyer with more than 13 years' experience working in-house within the pharmaceutical and life sciences sector, which follows 10 years in the private sector. Daniel joins Achilles from Intercept Pharmaceutical where he was vice president, Legal with responsibility for all legal outside of the US. Daniel has an MA in Law from Cambridge University and is enrolled as a solicitor in England & Wales and Ireland.

## Anaveon

Developing biologics to modulate the function of cytokines and provide substantial benefit to cancer patients.

### Key Announcements

[Anaveon Corporate Presentation](#)

12.06.2020

[Link to presentation.](#)

## Autolus

Developing next generation programmed T cell therapies for the treatment of cancer

### Key Media Coverage

[Autolus: Progress Developing Next Generation Car-T Therapies Ought To Lift Share Price](#)

08.07.2020

Edmund Ingham forecasts the potential for strong share price growth for Autolus over the next 12-18 months highlighting the recent strong progress with its AUTO1 and AUTO3 programme and notes that there are “numerous” catalysts to come in 2020 and 2021 with a pipeline of further candidates in development.

## Freeline

Focused on developing curative gene therapies for chronic systemic diseases

### Key Announcements

#### [Freeline closes \\$120m Series C Financing Round](#)

30.06.2020

Freeline announced the expansion of its Series C financing to \$120m raising a further \$80 million from specialist global institutional investors including Novo Holding A/S, Eventide Asset Management, Wellington Management Company, Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund. Syncona had invested \$40m in the round in December 2019 and its holding in Freeline was written up to £181.5m, an uplift of £30.8m (4.6p per share); 20.4% uplift to 31 March 2020. Syncona's ownership stake in the business is 60%.

#### [New data presented at the International Society on Thrombosis and Haemostasis](#)

13.07.2020

Announcement of new data on Freeline's AAV gene therapy product candidate, FLT180a, in severe Haemophilia B at ISTH 2020. The oral presentation was given by Professor Pratima Chowdary of Royal Free Hospital UK and UCL Cancer Institute. Reportable data is available for 10 patients who have been treated with FLT180a across 4 dose cohorts. The company has demonstrated with data up to two years for the earliest cohort, that a dose of between  $7.5 \times 10^{11}$  and  $9.75 \times 10^{11}$  vg/kg has the potential to create durable Factor IX (FIX) activity levels in the normal range in patients with severe Haemophilia B.

#### [Registration statement filed for proposed initial IPO in the US](#)

20.07.2020

Freeline announced it has filed a registration statement relating to a proposed initial public offering in the United States of its American Depositary Shares, each representing one ordinary share. Listing has been applied to its ADSs on The Nasdaq Global Select Market under FRLN.

### Key Media Coverage

#### [Syncona's Freeline mulls IPO after crossovers back gene therapy play](#)

BioCentury 01.07.20

Freeline CEO, Theresa Heggie spoke to BioCentury about the company's expanded Series C financing, talked about how Freeline's plans to use the additional funding and the potential of an IPO in the US. The funds will be used to support ongoing trials of its two clinical programs to treat systemic diseases: FLT180a to treat haemophilia B and FLT190 to treat Fabry disease. Heggie commented that "there are many other diseases that could be addressed by our platform, but not by others, because they require high levels of protein expression," adding that the company may look at inflammatory disease in the future.

#### [Freeline nabs \\$120M, eyes IPO as its gene therapy comes into focus](#)

Endpoints 01.07.20

Jason Mast of Endpoints also covered Freeline's latest financing round, commenting on how gene therapy is really coming into focus for the life sciences sector. As an example of the increasing appetite for gene therapy, Jason cited last year's sale of Nightstar Therapeutics, which was acquired by Biogen from Syncona for nearly \$1bn.

#### [As trio of companies enter IPO queue, four more propose terms](#)

BioCentury 21.07.20

In an article about the red-hot IPO market for biotech in the US, Paul Bonanos highlighted how Freeline registered its intent for an IPO on NASDAQ. Bonanos referenced how Freeline's two clinical gene therapies to treat haemophilia B and Fabry disease are based on a platform that optimises the therapies' potency, delivering high amounts of protein at a relatively low dose.



## OMass

Harnessing native mass spectrometry to drug drive discovery in high definition

### Key Announcements

#### [Appointment of Dr Nathalie Franchimont as Non-Executive Director](#)

28.07.2020

Nathalie brings more than 15 years of leadership experience in biotechnology and pharma industries. Nathalie currently leads development in Multiple Sclerosis and Immunology at Biogen, as VP, Head of MS and Immunology Development Unit. She has also previously held a variety of leadership roles at Biogen. Nathalie is a rheumatologist; trained as a M.D., Ph.D. at the University of Liège and has held research fellowship roles at the University of Connecticut School of Medicine, Yale University School of Medicine and University of Liège.